Estrogen and progestogen therapy in postmenopausal women

Fertility and Sterility

Volumn 90, Issue 5 SUPPL., 2008, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CONJUGATED ESTROGEN; CYPROTERONE; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO; VITAMIN D; WARFARIN;

ARTICLE; ATROPHY; BLEEDING; BREAST CANCER; BREAST TENDERNESS; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG EFFICACY; ENDOMETRIUM CANCER; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIP FRACTURE; HORMONAL THERAPY; HOT FLUSH; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MASTALGIA; MENOPAUSAL SYNDROME; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OSTEOPOROSIS; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SENILE DEMENTIA; SIDE EFFECT; SPOTTING; STROKE; TREATMENT DURATION; TREATMENT OUTCOME; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; UTERUS BLEEDING; VAGINA BLEEDING; VAGINAL DRYNESS; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; CORONARY DISEASE; EPIDEMIOLOGIC STUDIES; ESTROGENS; FEMALE; FEMALE UROGENITAL DISEASES; GENITAL NEOPLASMS, FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; PROGESTINS; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 55449126048     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.08.091     Document Type: Article

References (112)

1. Greendale G.A., Reboussin B.A., Hogan P., Barnabei V.M., Shumaker S., Johnson S., et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 92 (1998) 982-988
2. Barnabei V.M., Grady D., Stovall D.W., Cauley J.A., Lin F., Stuenkel C.A., et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 100 (2002) 1209-1218
3. Hays J., Ockene J.K., Brunner R.L., Kotchen J.M., Manson J.E., Patterson R.E., et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348 (2003) 1839-1854
4. MacLennan A.H., Broadbent J.L., Lester S., and Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 4 (2004) CD002978
5. American College of Obstetricians and Gynecologists Women's Health Care Physicians. Vasomotor symptoms. Obstet Gynecol 104 Suppl (2004) 106S-117S
6. Nelson H.D. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 291 (2004) 1610-1620
7. Wiklund I., Karlberg J., and Mattson L.A. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 168 (1993) 824-830
8. Ditkoff E.C., Crary W.G., Cristo M., and Lobo R.A. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 78 (1991) 991-995
9. Magos A., Brewster E., Singh R., O'Dowd T., Bruncat M., and Studd J.W.W. The effects of norethisterone in menopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome. Br J Obstet Gynaecol 93 (1986) 1290-1296
10. Borges L.E., Andrade R.P., Aldrighi J.M., Guazelli C., Yazlle M.E., Isaia C.F., et al. Effect of a combination of ethinylestradiol 30 μg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception. Contraception 74 (2006) 446-450
11. Cardozo L., Bachmann G., McLish D., Fonda D., and Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 92 (1998) 722-727
12. Fantl J.A., Cardozo L., and McLish D.K. Hormones and Urogenital Therapy Committee: Estrogen therapy in the management of urinary incontinence in postmenopausal women: first report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 83 (1994) 12-18
13. Grady D., Brown J.S., Vittinghoff E., Applegate W., Varner E., and Snyder T. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 97 (2001) 116-120
14. Hendrix S.L., Cochrane B.B., Nygaard I.E., Handa V.L., Barnabei V.M., Iglesia C., et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA 293 (2005) 935-948
15. Ryan P.J., Harrison R., Blake G.M., and Fogelman I. Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. Br J Obstet Gynaecol 99 (1992) 325-328
16. Archer D.F., and Pickar J.H. Hormone replacement therapy: effect of progestin dose and time since menopause on endometrial bleeding. Obstet Gynecol 96 (2000) 899-905
17. Archer D.F., Pickar J.H., and Bottliglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 83 (1994) 686-692
18. Pilon D., Castilloux A.-M., and Lelorier J. Estrogen replacement therapy: determinants of persistence with treatment. Obstet Gynecol 97 (2001) 97-100
19. Cherry N., Gilmour K., Hannaford P., Heagerty A., Khan M.A., Kitchener H., et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 360 (2002) 2001-2008
20. Anderson G.L., Judd H.L., Kaunitz A.M., Barad D.H., Beresford S.A., Pettinger M., et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 290 (2003) 1739-1748
21. Barnabei V.M., Cochrane B.B., Aragaki A.K., Nygaard I., Williams R.S., McGovern P.G., et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 105 (2005) 1063-1073
22. Cummings S.R., and Melton L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet 359 (2002) 1761-1767
23. Speroff L., Rowan J., Symons J., Genant H., and Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study) (a randomized controlled study). JAMA 276 (1996) 1397-1403
24. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women (Heart and Estrogen/progestin Replacement Study (HERS) Research Group). JAMA 280 (1998) 605-613
25. Komulainen M.H., Kroger H., Tuppurainen M.T., Heikkinen A.M., Alhava E., Honkanen R., et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women: a 5 year randomized trial. Maturitas 31 (1998) 45-54
26. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288 (2002) 321-333
27. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
28. Heiss G., Wallace R., Anderson G.L., Aragaki A., Beresford S.A., Brzyski R., et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 99 (2008) 1036-1045
29. Ott A., Breteler M.M., van Harskamp F., Stijnen T., and Hofman A. Incidence and risk of dementia: the Rotterdam Study. Am J Epidemiol 147 (1998) 574-580
30. LeBlanc E.S., Janowsky J., Chan B.K.S., and Nelson H.D. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 285 (2001) 1489-1499
31. Baldereschi M., Di Carlo A., Lepore V., Bracco L., Maggi S., Grigoletto F., et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology 50 (1998) 996-1002
32. Seshadri S., Zornberg G.L., Derby L.E., Myers M.W., Jick H., and Drachman D.A. Postmenopausal estrogen replacement therapy and risk of Alzheimer disease. Arch Neurol 58 (2001) 435-440
33. Slooter A.J., Bronzova J., Witteman J.C., Van Broeckhoven C., Hofman A., and van Duijn C.M. Estrogen use and early onset Alzheimer's disease: a population-based study. J Neurol Neurosurg Psychiatry 67 (1999) 779-781
34. Grodstein F., Chen J., Pollen D.A., Albert M.S., Wilson R.S., Folstein M.F., et al. Postmenopausal hormone therapy and cognitive function in healthy older women. J Am Geriatr Soc 48 (2000) 746-752
35. Maki P.M., Gast M.J., Vieweg A.J., Burriss S.W., and Yaffe K. Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial. Neurology 69 (2007) 1322-1330
36. Shumaker S.A., Legault C., Rapp S.R., Thal L., Wallace R.B., Ockene J.K., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women (the Women's Health Initiative Memory study: a randomized controlled trial). JAMA 289 (2003) 2651-2662
37. Rapp S.R., Espeland M.A., Shumaker S.A., Henderson V.W., Brunner R.L., Manson J.E., et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women (the Women's Health Initiative Memory Study: a randomized controlled trial). JAMA 289 (2003) 2663-2672
38. Shumaker S.A., Legault C., Kuller L.H., Rapp S.R., Thal L., Lane D.S., et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291 (2005) 2947-2958
39. WHO Scientific Group on Research on the Menopause in the 1990's. Research on the Menopause in the 1990's (1996), World Health Organization, Geneva
40. Grodstein F., Manson J.E., Colditz G.A., Willett W.C., Speizer F.E., and Stampfer M.J. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133 (2000) 933-941
41. Collins J. Benefits and risks of hormone replacement therapy. Medicine 29 (2001) 5-11
42. Herrington D.M., Reboussin D.M., Brosnihan K.B., Sharp P.C., Shumaker S.A., Snyder T.E., et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 343 (2000) 522-529
43. Angerer P., Stork S., Kothny W., Schmitt P., and von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol 21 (2001) 262-268
44. PEPI Trial Writing Group. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 273 (1995) 199-208
45. Shlipak M.G., Simon J.A., Vittinghoff E., Lin F., Barrett-Connor E., Knopp R.H., et al. Estrogen and progestin, lipoprotein (a), and risk of recurrent coronary heart disease events after menopause. JAMA 283 (2000) 1845-1852
46. Hodis H.N., Mack W.J., Azen S.P., Lobo R.A., Shoupe D., Mahrer P.R., et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 349 (2003) 535-545
47. Hsia J., Langer R.D., Manson J.E., Kuller L., Johnson K.C., Hendrix S.L., et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 166 (2006) 357-365
48. Manson J.E., Hsia J., Johnson K.C., Rossouw J.E., Assaf A.R., Lasser N.L., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 (2003) 523-534
49. Rossouw J.E., Prentice R.L., Manson J.E., Wu L., Barad D., Barnabei V.M., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297 (2007) 1465-1477
50. Manson J.E., Allison M.A., Rossouw J.E., Carr J.J., Langer R.D., Hsia J., et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 356 (2007) 2591-2602
51. Salpeter S.R., Walsh J.M., Greyber E., Ormiston T.M., and Salpeter E.E. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 19 (2004) 791-804
52. Tannen R.L., Weiner M.G., Xie D., and Barnhart K. A simulation using data from a primary care practice database closely replicated the women's health initiative trial. J Clin Epidemiol 60 (2007) 686-695
53. Tannen R.L., Weiner M.G., Xie D., and Barnhart K. Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. Hum Reprod 22 (2007) 1769-1777
54. Vittinghoff E., Shlipak M.G., Varosy P.D., Furberg C.D., Ireland C.C., Khan S.S., et al. Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med 138 (2003) 81-89
55. Manson J.E., Greenland P., LaCroix A.Z., Stefanick M.L., Mouton C.P., Oberman A., et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med 347 (2003) 716-725
56. Weinstein A.R., Sesso H.D., Lee I.M., Rexrode K.M., Cook N.R., Manson J.E., et al. The joint effects of physical activity and body mass index on coronary heart disease risk in women. Arch Intern Med 168 (2008) 884-890
57. Walsh J.M., and Pignone M. Drug treatment of hyperlipidemia in women. JAMA 291 (2004) 2243-2252
58. Ridker P.M., Cook N.R., Lee I.M., Gordon D., Gaziano J.M., Manson J.E., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1293-1304
59. Warren M.P. A comparative review of the risks and benefits of hormone replacement therapy regimens. Am J Obstet Gynecol 190 (2004) 1141-1167
60. Nanda K., Bastian L.A., Hasselblad V., and Simel D.L. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 93 (1999) 880-888
61. Grodstein F., Newcomb P.A., and Stampfer M.J. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 106 (1999) 574-582
62. Hulley S., Furberg C., Barrett-Connor E., Cauley J., Grady D., Haskell W., et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 (2002) 58-66
63. Chlebowski R.T., Wactawski-Wende J., Ritenbaugh C., Hubbell F.A., Ascensao J., Rodabough R.J., et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350 (2004) 991-1004
64. Grodstein F., Manson J.E., Colditz G.A., Willett W.C., and Speizer F.E. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133 (2000) 933-941
65. Simon J.A., Hsia J., Cauley J.A., Richards C., Harris F., Fong J., et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation 103 (2001) 638-642
66. Paganini-Hill A. Hormone replacement therapy and stroke: risk, protection or no effect?. Maturitas 38 (2001) 243-261
67. Goldstein L.B., Adams R., Becker K., Furberg C.D., Gorelick P.B., Hademenos G., et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 103 (2001) 163-182
68. Hart R.G., Pearce L.A., McBride R., Rothbart R.M., and Asinger R.W. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials (the Stroke Prevention in Atrial Fibrillation (SPAF) Investigators). Stroke 30 (1999) 1223-1229
69. Wassertheil-Smoller S., Hendrix S.L., Limacher M., Heiss G., Kooperberg C., Baird A., et al. Effect of estrogen plus progestin on stroke in postmenopausal women (the Women's Health Initiative: a randomized trial). JAMA 289 (2003) 2673-2684
70. Viscoli C.M., Brass L.M., Kernan W.N., Sarrel P.M., Suissa S., and Horwitz R.I. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345 (2001) 1243-1249
71. Curb J.D., Prentice R.L., Bray P.F., Langer R.D., Van Horn L., Barnabei V.M., et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 166 (2006) 772-780
72. Miller J., Chan B.K.S., and Nelson H.D. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 136 (2002) 680-690
73. Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., and Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348 (1996) 977-980
74. Devor M., Barrett-Connor E., Renvald M., Feigal D., and Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 92 (1992) 275-282
75. Grodstein F., Stampfer M.J., Goldhaber S.Z., Manson J.E., Colditz G.A., Speizer F.E., et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 348 (1996) 983-987
76. Perez Gutthann S., Garcia Rodriguez L.A., Castellsague J., and Oliart A.D. Hormone replacement therapy and risk of venous thromboembolism: population based case control study. BMJ 314 (1997) 796-800
77. Jick H., Derby L.E., Wald Myers M., Vasilakis C., and Newton K.M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348 (1996) 981-983
78. Scarabin P.Y., Oger E., and Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism. Lancet 362 (2003) 428-432
79. Varas-Lorenzo C., Garcia-Rodriguez L.A., Cattaruzzi C., Troncon M.G., Agostinis L., and Perez-Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol 147 (1998) 387-390
80. Canonico M., Plu-Bureau, Lowe G.D., and Scarabin P.Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 336 (2008) 1227-1231
81. Collins J.A., and Schlesselman J.J. Hormone replacement therapy and endometrial cancer. In: Lobo R.A. (Ed). Treatment of the postmenopausal woman (1999), Lippincott Williams and Wilkins, Philadelphia 503-512
82. Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365 (2005) 1543-1551
83. ESHRE Capri Workshop Group. Hormones and breast cancer. Hum Reprod Update 10 (2004) 281-293
84. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiologic studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 350 (1997) 1047-1059
85. Collins J.A., Crosignani P.G., and Blake J.M. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 11 (2005) 545-560
86. Stefanick M.L., Anderson G.L., Margolis K.L., Hendrix S.L., Rodabough R.J., Paskett E.D., et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295 (2006) 1647-1657
87. Chlebowski R.T., Hendrix S.L., Langer R.D., Stefanick M.L., Gass M., Lane D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative Randomized Trial. JAMA 289 (2003) 3243-3253
88. Nachtigall L.E., Nachtigall R.H., Nachtigall R.D., and Beckman E.M. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 54 (1979) 74-78
89. Prentice R.L., Chlebowski R.T., Stefanick M.L., Manson J.E., Langer R.D., Pettinger M., et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol 167 (2008) 1407-1415
90. Prentice R.L., Chlebowski R.T., Stefanick M.L., Manson J.E., Pettinger M., Hendrix S.L., et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 167 (2008) 1207-1216
91. Chlebowski R.T., Chen Z., Anderson G.L., Rohan T., Aragaki A., Lane D., et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97 (2005) 439-448
92. Rosenberg L., Palmer J.R., Wise L.A., and Adams-Campbell L.L. A prospective study of female hormone use and breast cancer among black women. Arch Intern Med 166 (2006) 760-765
93. Flesch-Janys D., Slanger T., Mutschelknauss E., Kropp S., Obi N., Vettorazzi E., et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 123 (2008) 933-941
94. Fournier A., Berrino F., and Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107 (2008) 103-111
95. Opatrny L., Dell'Aniello S., Assouline S., and Suissa S. Hormone replacement therapy use and variations in the risk of breast cancer. BJOG 115 (2008) 169-175
96. Beral VMillion Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
97. Schairer C., Gail M., Byrne C., Rosenberg P.S., Sturgeon S.R., Brinton L.A., et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 91 (1999) 264-270
98. Holmberg L., and Anderson H. HABITS (Hormonal Replacement Therapy After Breast Cancer-Is It Safe?), a randomised comparison: trial stopped. Lancet 363 (2004) 453-455
99. Singletary S.E. Rating the risk factors for breast cancer. Ann Surg 237 (2003) 474-482
100. Clemons M., and Goss P. Estrogen and the risk of breast cancer. N Engl J Med 344 (2001) 276-285
101. DevCan: Probability of Developing or Dying of Cancer Software. Version 5.2 (2004), Statistical Research and Applications Branch, U.S. National Cancer Institute, Bethesda, MD. http://srab.cancer.gov/devcan/ Available at:
102. Cramer D.W., Hutchison G.B., Welch W.R., Scully R.E., and Ryan K.J. Determinants of ovarian cancer risk. 1. Reproductive experiences and family history. J Natl Cancer Inst 71 (1983) 711-716
103. Hildreth N.G., Kelsey J.L., LiVolsi V.A., Fischer D.B., Holford T.R., Mostow E.D., et al. An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol 114 (1981) 398-405
104. Hartge P., Whittemore A.S., Itnyre J., McGowan L., and Cramer D. Rates and risks of ovarian cancer in subgroups of white women in the United States. Collaborative Ovarian Cancer Group. Obstet Gynecol 84 (1994) 760-764
105. Coughlin S.S., Giustozzi A., Smith S.J., and Lee N.C. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 53 (2000) 367-375
106. Bosetti C., Negri E., Franceschi S., Trichopoulos D., Beral V., La Vecchia C., et al. Relationship between postmenopausal hormone replacement therapy and ovarian cancer. JAMA 285 (2001) 3089-3090
107. Riman T., Dickman P.W., Nilsson S., Correia N., Nordlinder H., Magnusson C.M., et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 94 (2002) 497-504
108. Lacey J.V., Mink P.J., Lubin J.H., Sherman M.E., Troisi R., Hartge P., et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288 (2002) 334-341
109. Sit A.S.Y., Modugno F., Weissfeld J.L., Berga S.L., and Ness R.B. Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecol Oncol 86 (2002) 118-123
110. Folsom A.R., Anderson J.P., and Ross J.A. Estrogen replacement therapy and ovarian cancer. Epidemiology 15 (2004) 100-104
111. Glud E., Kjaer S.K., Thomsen B.L., Hogdall C., Christensen L., Hogdall E., et al. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 164 (2004) 2253-2259
112. Rodriguez C., Patel A.V., Calle E.E., Jacob E.J., and Thun M.J. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285 (2001) 1460-1465